Update on legal proceedings
(Thomson Reuters ONE) -
H. Lundbeck A/S (Lundbeck) has been informed of a favorable ruling from the City
Court in Elsinore in a preliminary injunction case in Denmark. The decision
means that generic versions of escitalopram in Denmark have to be removed from
the market. The decision can be appealed by the other side.
At the same time Lundbeck has received the outcome of a preliminary injunction
case, held before the Commercial Court of Barcelona, regarding infringement of
the escitalopram patent in Spain.
The court decided to lift the ex parte injunction made against companies
preparing to market a generic version of escitalopram in Spain. Lundbeck does
not agree with the court ruling and will appeal the decision.
As a result of the ruling Lundbeck expects generic versions of escitalopram to
be available in Spain within a short period of time. The entrance of generic
versions into the market is expected to have a moderate impact on Cipralex(®)
sales on the Spanish market in 2010.
A prerequisite for Lundbeck's continued investments in innovative
pharmaceuticals is that intellectual property rights are respected. As the
Lundbeck Group's intellectual property rights are valid and hence enforceable,
it is Lundbeck's policy to enforce its intellectual property rights, wherever
they may be violated.
Financial guidance
The content of this release will have no influence on the Lundbeck Group's
financial guidance for 2010.
Lundbeck contacts
Investors: Media:
Jacob Tolstrup Mads Kronborg
Vice President, IR & Communication Media Relations Manager
+45 36 43 30 79 +45 36 43 28 51
Palle Holm Olesen Stine Hove Marsling
Chief Specialist; Investor Relations External Communication Specialist
+45 36 43 24 26 +45 36 43 28 33
Magnus Thorstholm Jensen
Investor Relations Officer
+45 36 43 38 16
About Lundbeck
H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international pharmaceutical
company highly committed to improve the quality of life for people suffering
from central nervous system (CNS) disorders. For this purpose Lundbeck is
engaged in the research and development, production, marketing and sale of
pharmaceuticals across the world, targeted at disorders like depression and
anxiety, schizophrenia, insomnia, Huntington's, Alzheimer's and Parkinson's
diseases.
Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark, and
employs today approximately 5,900 people worldwide. Lundbeck is one of the
world's leading pharmaceutical companies working with CNS disorders. In 2009,
the company's revenue was DKK 13.7 billion (approximately EUR 1.8 billion or USD
2.6 billion). For more information, please visit www.lundbeck.com.
[HUG#1404616]
Release no 401: http://hugin.info/130085/R/1404616/358698.pdf
Unternehmensinformation / Kurzprofil:
Datum: 16.04.2010 - 14:00 Uhr
Sprache: Deutsch
News-ID 19190
Anzahl Zeichen: 0
contact information:
Town:
Valby
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 321 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Update on legal proceedings"
steht unter der journalistisch-redaktionellen Verantwortung von
H. Lundbeck A/S (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
